Q4 2023 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2024-02-14 · accession 0001892134-24-000002
$1.87B
Reported value
49
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $191.7M | 10.3% | 6,495,392 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $157.0M | 8.39% | 9,781,472 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $135.5M | 7.25% | 12,131,705 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $122.6M | 6.56% | 988,460 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $110.0M | 5.88% | 2,725,949 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $109.0M | 5.83% | 2,371,304 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $92.3M | 4.93% | 10,109,279 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $73.1M | 3.91% | 1,164,405 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $59.9M | 3.20% | 3,014,349 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $59.7M | 3.19% | 3,131,008 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $53.0M | 2.83% | 885,165 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $45.6M | 2.44% | 1,523,013 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $45.3M | 2.42% | 785,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $44.4M | 2.37% | 3,622,294 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $36.2M | 1.94% | 1,787,527 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $29.2M | 1.56% | 2,667,203 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $28.6M | 1.53% | 997,455 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $28.5M | 1.52% | 1,388,889 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $28.3M | 1.51% | 8,764,232 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $27.3M | 1.46% | 1,204,867 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $24.1M | 1.29% | 3,746,857 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $23.1M | 1.24% | 2,401,704 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $22.9M | 1.22% | 730,917 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $22.3M | 1.19% | 2,000,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $20.5M | 1.10% | 746,479 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $19.7M | 1.05% | 2,142,855 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $19.3M | 1.03% | 899,700 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $18.8M | 1.01% | 4,000,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $18.7M | 1.00% | 464,937 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $16.7M | 0.89% | 393,000 | Common | SOLE |
| 24344T101 | DCPHEUR | DECIPHERA PHARMACEUTICALS IN | $16.5M | 0.88% | 1,021,800 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $16.1M | 0.86% | 69,406 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $15.8M | 0.84% | 1,184,840 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $15.3M | 0.82% | 881,173 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $14.2M | 0.76% | 1,026,420 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $14.1M | 0.76% | 397,483 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $12.9M | 0.69% | 317,190 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $11.7M | 0.63% | 285,331 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $11.7M | 0.63% | 1,995,267 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $11.7M | 0.62% | 523,166 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $11.2M | 0.60% | 400,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $9.9M | 0.53% | 7,381,090 | Common | SOLE |
| 88369M101 | — | THESEUS PHARMACEUTICALS INC | $8.6M | 0.46% | 2,118,051 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $6.2M | 0.33% | 203,684 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $4.7M | 0.25% | 80,000 | Common | SOLE |
| 09609G100 | — | BLUEBIRD BIO INC | $2.4M | 0.13% | 1,709,907 | Common | SOLE |
| 39868T105 | 2JQ | GRITSTONE BIO INC | $2.1M | 0.11% | 1,030,878 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $1.6M | 0.08% | 500,333 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $277,596 | 0.01% | 264,377 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.